Skip to content

A clinical study to evaluate the anti-fatigue effect of hydrogen water

A clinical study to evaluate the anti-fatigue effect of hydrogen water - The anti-fatigue effect of hydrogen water

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027700
Enrollment
20
Registered
2018-11-30
Start date
2017-06-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Sponsors

Soiken Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy subjects aged from 30 to 60 years (bounds included) 2) Subject whose serum d-ROMs level between 301 U.CARR to 400 U.CARR (bounds included) 3) Subject having a briefing of the content of the present study, fully understanding and agreeing to its objective and being able to personally sign a written informed consent

Exclusion criteria

Exclusion criteria: 1) Subject receiving a medical treatment for serious renal, hepatic, cardio-vascular, respiratory, endocrine or metabolic disorders or having a medical history of these disorders 2) Subject having the chronic fatigue syndrome (CFS), or subject deemed to have severe fatigue such as idiopathic chronic fatigue by the investigator 3) Subject who takes regularly medicine or quasi-drugs which having the efficacy on recovery of fatigue or nutrition in cases of physical fatigue 4) Subject who regularly takes hydrogen water 5) Subject having blood sample of 200 ml or more taken within 1 month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood) 6) Subject who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study 7) Female subject who is pregnant or lactating, or intending to become pregnant during the study 8) Subject deemed unsuitable by the investigator

Design outcomes

Primary

MeasureTime frame
Visual analogue scale (VAS)

Secondary

MeasureTime frame
Advanced trail making test (ATMT) , Chalder fatigue scale, autonomic nervous system function(spectrum analysis of a-a intervals on accelerated plethysmography), d-ROMs, BAP, OSI, hs-CRP, ox-LDL, cortisol, urinary 8-isoprostane, urinary 8-OHdG

Countries

Japan

Contacts

Public ContactTomohiro Sugino

Soiken Inc. Representative Director

sugino@soiken.com06-6871-8888

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026